Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772235 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10459187 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9945534 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL29674419 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19509816 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL22984018 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19509705 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4287258 | 0.92 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9945527 | 0.90 | P2RY12 (0.41) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL15892163 | 0.89 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220306679-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | DICERNA PHARMACEUTICALS, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4021915-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021041756-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-2331558-B1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | AGILENT TECHNOLOGIES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-8841275-B2 | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120142626-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2010-03-25 | — | — | US | disclosed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
| EP-0541742-A1 | 2',5'-NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992021691-A1 | 2',5'-NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306679-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | NSUN2, NSUN3, AGO2 | PDE4A 4049/4885PDE4B 3917/4885PDE4C 3808/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | PDE4A 4353/4885PDE4B 4402/4885PDE4C 3851/4885 |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | PDE4A 1011/4885PDE4B 1054/4885PDE4C 857/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | PDE4A 3652/4885PDE4B 3841/4885PDE4C 2966/4885 |
| US-20120142626-A1 | COMPOUNDS | HAVCR2, EIF2AK2, NTPCR | PDE4A 1180/4885PDE4B 1210/4885PDE4C 1211/4885 |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | PDE4A 3760/4885PDE4B 3497/4885PDE4C 3081/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | PDE4A 2603/4885PDE4B 3041/4885PDE4C 2418/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | PDE4A 2377/4885PDE4B 2731/4885PDE4C 2324/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | PDE4A 3652/4885PDE4B 3841/4885PDE4C 2966/4885 |
| US-20160002282-A1 | Protected Monomer and Method of Final Deprotection for RNA Synthesis | NSUN2, SNRPB2, RNGTT | PDE4A 4353/4885PDE4B 4402/4885PDE4C 3851/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | PDE4A 4102/4885PDE4B 3699/4885PDE4C 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.